PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
International Journal of Cancer10.1002/ijc.2905320141364928-935Sensitivity, effect and overdiagnosis in screening for cancers with detectable pre-invasive phaseMatti Hakama, Arun Pokhrel, Nea Malila, Timo Hakulinenhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.29053
Journal of Medical Screening10.1258/09691410539082672005122107-108Mammographic screening only matters in the detectable preclinical period of breast cancerMJM Broeders, ALM Verbeekhttp://journals.sagepub.com/doi/pdf/10.1258/0969141053908267, http://journals.sagepub.com/doi/pdf/10.1258/0969141053908267
Statistics in Medicine10.1002/sim.4780141404199514141531-1543Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phaseStephen W. Duffy, Hsiu-Hsi Chen, Laszlo Tabar, Nicholas E. Dayhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fsim.4780141404, https://onlinelibrary.wiley.com/doi/full/10.1002/sim.4780141404
Anticancer Drug Development Guide10.1007/978-1-4615-8152-9_151997289-292The Phase III Cancer Clinical TrialEmil Freihttp://link.springer.com/content/pdf/10.1007/978-1-4615-8152-9_15
Gynecologic Oncology10.1006/gyno.1999.5524199975155-61Estimation of the Duration of the Preclinical Phase of Cervical Adenocarcinoma Suggests That There Is Ample Opportunity for ScreeningSteven C. Plaxe, Sidney L Saltzsteinhttps://api.elsevier.com/content/article/PII:S0090825899955245?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0090825899955245?httpAccept=text/plain
JNCI: Journal of the National Cancer Institute10.1093/jnci/djx060201710910Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the MethodologyTheodora M Ripping, Kevin ten Haaf, André L M Verbeek, Nicolien T van Ravesteyn, Mireille J M Broedershttp://academic.oup.com/jnci/article-pdf/109/10/djx060/24648829/djx060.pdf
British Journal of Cancer10.1038/sj.bjc.6601355200389101830-1833Extended duration of the detectable stage by adding HPV test in cervical cancer screeningM E van den Akker-van Marie, M van Ballegooijen, L Rozendaal, C J L M Meijer, J D F Habbemahttp://www.nature.com/articles/6601355.pdf, http://www.nature.com/articles/6601355, http://www.nature.com/articles/6601355.pdf
10.21203/rs.3.rs-64439/v22021Barriers and Facilitators for Cervical Cancer Screening Among Young Women: A Systematic Reviewhttps://www.researchsquare.com/article/rs-64439/v2, https://www.researchsquare.com/article/rs-64439/v2.html
10.21203/rs.3.rs-1654784/v12022A Systematic Review on Evolving the Bowel Cancer Screening Programme in England: Targeted Screening for Individuals with First-Degree Family History of Bowel CancerRutendo Lisa Chigondahttps://www.researchsquare.com/article/rs-1654784/v1, https://www.researchsquare.com/article/rs-1654784/v1.html
The Breast10.1016/j.breast.2019.03.00320194570-74Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancerA.M.W.M. Aarts, S.W. Duffy, S.M.E. Geurts, D.P. Vulkan, N. Houssami, M. Zappa, I.D. Nagtegaal, A.L.M. Verbeek, M.J.M. Broedershttps://api.elsevier.com/content/article/PII:S0960977619300426?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977619300426?httpAccept=text/plain